Share on StockTwits

Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) have been given a consensus recommendation of “Buy” by the twelve ratings firms that are presently covering the company, AnalystRatings.NET reports. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $23.10.

Several analysts have recently commented on the stock. Analysts at FBR Capital Markets initiated coverage on shares of Keryx Biopharmaceuticals in a research note on Wednesday. They set a “market perform” rating and a $16.00 price target on the stock. Separately, analysts at Mizuho cut their price target on shares of Keryx Biopharmaceuticals from $32.00 to $30.00 in a research note on Friday, August 8th. Finally, analysts at HC Wainwright reiterated a “buy” rating on shares of Keryx Biopharmaceuticals in a research note on Friday, May 23rd. They now have a $19.00 price target on the stock.

Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) opened at 16.74 on Monday. Keryx Biopharmaceuticals has a 1-year low of $8.29 and a 1-year high of $17.46. The stock has a 50-day moving average of $15.27 and a 200-day moving average of $14.8. The company’s market cap is $1.537 billion.

Keryx Biopharmaceuticals (NASDAQ:KERX) last released its earnings data on Thursday, August 7th. The company reported ($0.24) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.25) by $0.01. During the same quarter last year, the company posted ($0.14) earnings per share. On average, analysts predict that Keryx Biopharmaceuticals will post $-0.89 earnings per share for the current fiscal year.

Keryx Biopharmaceuticals, Inc (NASDAQ:KERX) is focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.